Dr. Reddy's Laboratories (NYSE:RDY) Reaches New 12-Month Low - Should You Sell?

Dr. Reddy's Laboratories Limited (NYSE:RDY - Get Free Report) shares reached a new 52-week low during mid-day trading on Wednesday . The company traded as low as $13.22 and last traded at $13.20, with a volume of 115167 shares. The stock had previously closed at $13.56.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the stock. StockNews.com lowered shares of Dr. Reddy's Laboratories from a "buy" rating to a "hold" rating in a research report on Friday, December 6th. Barclays decreased their target price on Dr. Reddy's Laboratories from $17.40 to $17.00 and set an "overweight" rating for the company in a research report on Wednesday, November 6th. Finally, Nomura lowered Dr. Reddy's Laboratories from a "buy" rating to a "neutral" rating in a report on Thursday, December 19th.

Dr. Reddy's Laboratories Stock Down 0.8 %

The company has a market capitalization of $11.13 billion, a PE ratio of 21.23 and a beta of 0.50. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.38 and a current ratio of 1.92. The stock's 50 day moving average is $14.63 and its 200 day moving average is $15.19.

Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last posted its quarterly earnings results on Thursday, January 23rd. The company reported $0.20 EPS for the quarter, topping analysts' consensus estimates of $0.19 by $0.01. Dr. Reddy's Laboratories had a return on equity of 17.87% and a net margin of 17.25%. On average, sell-side analysts anticipate that Dr. Reddy's Laboratories Limited will post 0.8 EPS for the current fiscal year.

Remove Ads

Institutional Investors Weigh In On Dr. Reddy's Laboratories

Several hedge funds and other institutional investors have recently modified their holdings of RDY. EverSource Wealth Advisors LLC grew its stake in Dr. Reddy's Laboratories by 423.3% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,863 shares of the company's stock valued at $29,000 after acquiring an additional 1,507 shares in the last quarter. Glass Jacobson Investment Advisors llc boosted its holdings in Dr. Reddy's Laboratories by 400.0% in the 4th quarter. Glass Jacobson Investment Advisors llc now owns 2,000 shares of the company's stock valued at $32,000 after purchasing an additional 1,600 shares during the period. Farther Finance Advisors LLC grew its position in Dr. Reddy's Laboratories by 43.2% during the third quarter. Farther Finance Advisors LLC now owns 454 shares of the company's stock worth $36,000 after buying an additional 137 shares in the last quarter. POM Investment Strategies LLC grew its holdings in shares of Dr. Reddy's Laboratories by 400.0% during the fourth quarter. POM Investment Strategies LLC now owns 2,275 shares of the company's stock worth $36,000 after purchasing an additional 1,820 shares in the last quarter. Finally, Allworth Financial LP grew its stake in Dr. Reddy's Laboratories by 447.8% in the 4th quarter. Allworth Financial LP now owns 2,728 shares of the company's stock worth $41,000 after buying an additional 2,230 shares in the last quarter. 3.85% of the stock is currently owned by institutional investors.

About Dr. Reddy's Laboratories

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.